Johns Hopkins University (JHU) and Exagen, a leading provider of autoimmune testing solutions, have signed an exclusive license agreement to develop and commercialize novel patented biomarkers for therapeutic management of patients with lupus nephritis.
The biomarkers were discovered in the lab of JHU researchers Michelle Petri and Andrea Fava. Through the license agreement, Exagen plans to develop the biomarkers into assays to aid diagnostic and treatment decisions by providing unique clinical insight into a specific patient’s lupus nephritis in a non-invasive manner.
“We are very excited to accelerate the development of these highly innovative biomarkers for lupus nephritis patient management,” says John Aballi, Exagen president and CEO.
“Exagen has a strong track record of serving clinicians in the autoimmune space,” Aballi adds. “Having the opportunity to work with this exceptional team further reinforces our commitment to developing novel technology in this space.”
Source: Yahoo! Finance
